China's Biotech Push: Implications for Western Pharma and Investors

Goldman Sachs US biotech analyst Salvine Richtor discusses her recent China biopharma trip and the country's five-year plan to capture 25% of global first-in-class drug share. The conversation examines how China's focus on me-too/better drugs, known targets, and modalities like antibody drugs and cancer vaccines may affect Western biotech product cycles and cross-border deal activity.

■ China's innovation focus
- Me-too/better drugs, re-engineered known targets, and moves into oncology, immunology, and obesity
- Antibody-based drugs, cancer vaccines, and early AI use for discovery and molecule design

■ Competitive and deal landscape
- Potential shorter product cycles and $440B in drugs going off patent by 2032
- Western pharma viewing China as a source of assets and business development
- Cross-border licensing and M&A examples involving Eli Lilly, Pfizer, AstraZeneca

■ AI, robotics, and investment implications
- AI for mining IP, early-stage discovery, trial design, and manufacturing; robotics in wet labs
- China-to-Western data translation, with Summit head-to-head data in frontline lung cancer as a key event

For investors, biotech analysts, and pharma strategy watchers, this provides a concise overview of China's biotech ambitions and the competitive dynamics shaping Western biotech.